ORIGINAL STUDIES

Chronic kidney disease is associated with increased mortality and procedural complications in transcatheter aortic valve replacement: a systematic review and meta-analysis

Pattara Rattanawong MD^{1,2} ^(D) | Chanavuth Kanitsoraphan MD¹ | Jakrin Kewcharoen MD¹ | Tanawan Riangwiwat MD³ ^(D) | Pitchaporn Chongyangyuenvong MD² | Wasawat Vutthikraivit MD⁴ | Santhosh R. Mannem MD⁵ | Eugene H. Chung MD, FHRS, FAHA, FACC⁶

¹Department of Internal Medicine, University of Hawaii Internal Medicine Residency Program, Honolulu, Hawaii

²Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

³Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania

⁴Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas

⁵Division of Cardiology, Queen's Medical Center, Honolulu, Hawaii

⁶Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, Michigan

Correspondence

Pattara Rattanawong, MD, University of Hawaii Internal Medicine Residency Program, Honolulu, HI 96813. Email: pattarar@hawaii.edu

Abstract

Objective: We performed a systematic review and meta-analysis to explore the association between chronic kidney disease (CKD) and mortality and procedural complications in transcatheter aortic valve replacement (TAVR).

Background: The impact of varying stages of CKD or end-stage renal disease (ESRD) on patients receiving TAVR is not clearly identified.

Methods: We searched the databases of MEDLINE and EMBASE from inception to May 2018. Included studies were published TAVR studies that compared the risk of mortality and procedural complications in CKD patients compared to control patients. Data from each study were combined using the random-effects model.

Results: Twelve studies (42,703 CKD patients and 51,347 controls) were included. Compared with controls, CKD patients had a significantly higher risk of 30-day overall mortality (risk ratio [RR] = 1.56, 95% confidence interval [CI]: 1.34–1.80, $I^2 = 60.9$), long-term cardiovascular mortality (RR = 1.44, 95% CI: 1.22–1.70, $I^2 = 36.2\%$), and long-term overall mortality (RR = 1.66, 95% CI: 1.45–1.91, $I^2 = 80.3$), as well as procedural complications including pacemaker requirement (RR = 1.20, 95% CI: 1.03–1.39, $I^2 = 56.1\%$) and bleeding (RR = 1.60, 95% CI: 1.26–2.02, $I^2 = 86.0\%$). Risk of mortality and procedural complications increased with severity of CKD for stages 3, 4, and 5, respectively, in terms of long-term overall mortality (RR = 1.28, 1.82, and 2.12), 30-day overall mortality (RR = 1.26, 1.89, and 1.93), 30-day cardiovascular mortality (RR = 1.18, 1.75, and 2.50), and 30-day overall bleeding (RR = 1.19, 1.63, and 2.12).

Conclusions: Our meta-analysis demonstrates a significant increased risk of mortality and procedural complications in patients with CKD who underwent TAVR compared to controls.

KEYWORDS

chronic kidney disease, transcatheter aortic valve replacement

1 | INTRODUCTION

Transcatheter aortic valve replacement (TAVR) is an increasingly common therapeutic procedure for symptomatic, moderate-severe aortic

Abbreviations: AS, aortic stenosis; CHS, cardiovascular health study; CKD, chronic kidney disease; ESRD, end-stage renal disease; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.

stenosis (AS). In these patients, this intervention is superior to medical therapy alone and has comparable results to the conventional surgical aortic valve replacement (SAVR).¹ TAVR is the treatment of choice for symptomatic AS in inoperable patients or patients with unacceptably high surgical risks.²

Decreased renal function is associated with worse outcomes in many cardiovascular conditions, such as atherosclerosis, heart failure,

pericardial and valvular disease, and outcomes of cardiac interventions.³ More than 75% of patients with severe AS may have some degree of renal dysfunction.^{4,5} Moreover, chronic kidney disease (CKD) is an independent risk factor for mid-term mortality in patients with AS undergoing SAVR and TAVR.⁶ The impact of varying stages of CKD or end-stage renal disease (ESRD) on patients receiving TAVR is not clearly identified.

We sought to determine the effect of different stages of CKD on both short and long-term overall and cardiovascular mortality in patients who underwent TAVR. Additional outcomes including pacemaker implantation, vascular complications, bleeding, and cerebrovascular accident were also evaluated.

2 | METHOD

2.1 | Search strategy

Two investigators (JK and PC) independently searched for published studies indexed in MEDLINE and EMBASE databases from inception to May 2018 using a search strategy, described in online Supporting information Document 1, that included the terms "chronic kidney disease", "aortic stenosis", "transcatheter aortic valve replacement", "complications", "vascular complications", "bleeding", "pacemaker", "cardiovascular mortality", and "mortality". Only English language publications were included. A manual search for additional pertinent studies and review articles using references from retrieved articles was also completed.

2.2 | Inclusion criteria

The eligibility criteria included the following:

(1) Cohort study (prospective or retrospective) reporting incident mortality and procedural complications after the TAVR procedure.

(2) Reported relative risk, odds ratio, hazard ratio, incidence ratio, or standardized incidence ratio with 95% confidence intervals (CIs), or sufficient raw data for their calculation.

(3) Participants without CKD as controls.

Study eligibility was independently determined by two investigators (TR and CK) and differences were resolved by mutual consensus. The Newcastle-Ottawa quality assessment scale was used to evaluate each study in three domains: recruitment and selection of the participants, similarity and comparability between the groups, and ascertainment of the outcome of interest among cohort studies.⁷

2.3 | Data extraction

A standardized data collection form was used to obtain the following information from each study: title of study, name of first author, year of study, year of publication, country of origin, number of participants, demographic data of participants, method used to identify cases and controls, method used to diagnose outcomes of interest (mortality and procedural complications), average duration of follow-up, confounders that were adjusted, adjusted effect estimates with 95% CI, and covariates that were adjusted for the multivariable analysis.

To ensure accuracy, all investigators independently performed this data extraction process. Any data discrepancy was resolved by referring back to the original articles.

2.4 | Definition of CKD

Chronic kidney disease was previously defined as the presence of kidney damage or decreased kidney function for three or more months, regardless of the cause, which was documented with International Classification of Diseases, Ninth Revision. The definition was introduced by the National Kidney Foundation, Kidney Disease Outcomes Quality Initiative, and modified by the international guideline group Kidney Disease Improving Global Outcomes.^{8,9} Chronic kidney diseases included in our study were CKD stages 3A to CKD stage 5 or glomerular filtration rate less than 60 mL/min/1.73 m². Patients with glomerular filtration rate more than or equal to 60 mL/min/1.73 m² were considered as part of the control group.

2.5 | Outcome definition

Outcomes (overall mortality, cardiovascular mortality, pacemaker requirement, overall bleeding, major bleeding, cerebrovascular accident, major vascular complications, and overall vascular complications) were adjudicated according to Valvular Academic Research Consortium (VARC) criteria.¹⁰ Long-term overall mortality was defined as over-all mortality at more than 30 days.

2.6 | Statistical analysis

We performed a meta-analysis of the included cohort studies using a random-effects model. Studies were excluded if they did not present an outcome in each intervention group or did not have enough information required for continuous data comparison. We pooled the point estimates of risk ratio (RR) and rate ratio from each study using the generic inverse-variance method of DerSimonian and Laird.¹¹ The heterogeneity of effect size estimates across these studies was quantified using the I^2 statistic. The I^2 statistic ranges in value from 0 to 100% (I^2 < 25%, low heterogeneity; $I^2 = 25\%-50\%$, moderate heterogeneity; and $I^2 > 50\%$, substantial heterogeneity).¹² A sensitivity analysis was performed to assess the influence of the individual studies on the overall results by omitting one study at a time. Publication bias was assessed using funnel plot and Egger's regression test¹³ (P < 0.05was considered significant). Potential sources of heterogeneity from clinical characteristics were analyzed with subgroup analysis and were compared with meta-regression. All data analyses were performed using Stata SE Statistical Software: Release 14.1, College Station, TX: StataCorp LP, StataCorp 2015.

2.7 | Sensitivity analysis

We used a sequential exclusion strategy, as described by Patsopoulos et al., to examine whether overall estimates were influenced by the substantial heterogeneity observed.¹⁴ In accordance with Cochrane, evidence of publication bias was examined through funnel plots if there were more than 10 available studies. Funnel plot

E118 WILEY-

asymmetry was further confirmed with Egger's test. If asymmetry was present, we used the trim-and-fill method to adjust for publication bias.

3 | RESULTS

3.1 | Description of included studies

Our search strategy yielded 908 potentially relevant articles (568 articles from EMBASE and 340 articles from MEDLINE). After exclusion of 14 duplicate articles, 894 articles underwent title and abstract review. Seven hundred and forty-seven articles were excluded at this stage since they were not cohort studies, did not report the outcome of interest (mortality or compilations) or were not conducted in patients with CKD, leaving 147 articles for full-length article review. One hundred and twenty-four of the 147 studies were excluded, as they were descriptive studies without comparators. Two studies were excluded because the same group of authors used the same database. Nine more studies were excluded because of unclear outcome definition. Therefore, eight retrospective and four prospective cohort studies with 42,703 CKD patients and 51,347 controls were included in this meta-analysis. Figure 1 outlines the search and literature review

process. Summaries of the included studies and the clinical characteristics are shown in Table 1.

3.2 | Meta-analysis results

Twelve studies (42,703 CKD patients and 51,347 controls) were included. Compared with controls, CKD patients had a significantly higher risk of 30-day overall mortality (RR = 1.56, 95% CI: 1.34–1.80, $I^2 = 60.9$) (Figure 2A) and 30-day cardiovascular mortality (RR = 1.47, 95% CI: 1.20–1.81, $I^2 = 13.2\%$) (Figure 2B). CKD patients had a significantly higher risk of long-term cardiovascular mortality (RR = 1.44, 95% CI: 1.22–1.70, $I^2 = 36.2\%$) (Figure 3A) and long-term overall mortality (RR = 1.66, 95% CI: 1.45–1.91, $I^2 = 80.3$) (Figure 3B).

Interestingly, risk of long-term overall mortality increased with severity of CKD for stages 3, 4, and 5, respectively (RR = 1.28, 1.82, and 2.12), 30-day overall mortality (RR = 1.26, 1.89, and 1.93), and 30-day cardiovascular mortality (RR = 1.18, 1.75, and 2.50).

Regarding procedural complications, CKD significantly increased risk of 30-day pacemaker requirement (RR = 1.20, 95% CI: 1.03–1.39, $I^2 = 56.1\%$) (Supporting information Figure S1), 30-day overall bleeding (RR = 1.60, 95% CI: 1.26–2.02, $I^2 = 86.0\%$), and 30-day major bleeding (RR = 1.40, 95% CI: 1.10–1.78, $I^2 = 88.2\%$) (Supporting information Figure S2). CKD increased the risk of 30-day major vascular complications




FIGURE 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram of search strategy and included studies [Color figure can be viewed at wileyonlinelibrary.com]

	rts		బ్	AVR. IS		hed D-fold	(Continues)
Conclusion by authors	Advanced CKD was associated with a higher rate of early and late mortality and bleeding events following TAVR	Patients with severe chronic renal disease presented higher risk of adverse events	Advanced CKD and dialysis are associated with increased rates of all-cause and CVS mortality, major and life- threatening bleeding, and vascular complications	CKD stages 3b to 5 increases the risk of mortality after TAVR and SAVR. The risk of AKI was higher after SAVR	Patients with CKD undergoing TAVR have a highter-risk profile and 1-vear 30-day and 1-vear outcomes. Chronic HD and severe preprocedural CKD are independently associated with an increased risk of 1-vear mortality after TAVR	The patients established on dialysis before TAVR had a > two-fold increased risk of mortality	(Cont
Outcome definition	Mortality, stoke, MI, bleeding complications, AKI, vascular complications, conduction disturbances and arrhythmias	Overall mortality, CVS mortality, MI, stroke, bleedings, vascular complications, pacemaker	Major bleeding, major vascular complications, device failure, new permanent pacemaker implantation, inhospital cerebrovascular accident	All-cause mortality up to 2 years, stroke, vascular complications, RBC transfusion, AKI	1-year survival, 30-day all-cause and CS mortality, MI, Stroke vascular and bleeding complications, AKI, device success, and 30-day combined safety end point	The incidence of dialysis requirement after TAVR	
Mean age (years)	80.5	82.4	81.5	79.9	81.0	82.9	
High STS score (%)	61.2	100	100	0	71.6	75.0	
	49.9	42.3	44.7	63.2	53.8	53.4	
Total population Male (%)							
Total popu	2,075	364	1,204	1,057	942	6,464	
Exposure group	CKD stages 1-2 (eGFR ≥ 60 mL/min/ 1.73 m ²), stage 3 (30–59 mL/min/ 1.73 m ²), stage 4 (15–29 mL/min/1.73 m ²) and stage 5 (<15 mL/min/1.73 m ²)	eGFR ≥ 60 mL/min/1.73 m ² , between 30 and 59 mL/min/1.73 m ² , and between 15 and 29 mL/min/1.73 m ²	eGFR: >60 mL/min/1.73 m ² (group 1), 31 to 60 mL/min/ 1.73 m ² (group 11), s30 mL/min/ 1.73 m ² (group 11), and dialysis (group 1V).	CKD stages 3b to 5	Normal eGFR (≥90 mL/min), mild (60–89 mL/min), moderate (30–59 mL/min) and severe (<30 mL/min) CKD and those on chronic hemodialysis (HD)	eGFR ≥ 60 mL/min/1.73 m ² ; 45–59 mL/min/1.73 m ² ; (KD stage 3a); 30–44 mL/min/1.73 m ² (KD stage 3b); 15–29 mL/min/ 1.73 m ² (KD stage 4); and < 15 mL/min/1.73 m ² (CKD stage 5)	
Exclusion criteria	Patients with end-stage kidney disease and previous dialysis	Patients with a dearance less than 15 mL/min/1.73 m ² or in dialysis	Advanced chronic renal dysfunction (CKD stages 4–5)	Porcelain aorta or hostile chest, undergoing coronary revascularization or intervention on other heart valves, underwent emergency procedures	Missing preprocedural serum creatinine, on chronic HD	Previously on dialysis	
Participant description	Consecutive patients who underwent TAVR	All TAVR patients of the institutions	Consecutive patients with severe symptomatic AS who underwent TAVR	All consecutive adult patients admitted with a diagnosis of severe AS who require an aortic valve replacement	All patients who underwent TAVR	All patients not requiring dialysis support before the TAVR procedure	
Setting of study	Hospital based	Hospital based	Hospital based	Hospital based	Hospital based	Hospital based	
Study design	Retrospective cohort study	2013 Prospective I cohort study	2016 Prospective 1 cohort study	2016 Prospective I cohort study	2013 Retrospective 1 cohort study	2017 Prospective 1 cohort study	
if Year	2014	2013	2016	2016	2013	2017	
Country of origin	Canada	Italy	Israel	ttaly	France	ž	
Author	Allende	D'Ascenzo Italy	Codher	D'errigo	Dumontiel France	Ferro	

 TABLE 1
 Summaries of the included studies and the clinical characteristics

	_	Preoperative CKD does not increase the risk of mortality and AKI after TAVR	tients with CKD or ESRD have worse in-hospital outcomes difer TAVR. AKI is associated with higher associated with higher in-hospital mortality in patients undergoing TAVR	Increasing CKD stage leads to an increased risk of death and/or RRT. Continuous analysis showed significant differences in outcomes in all levels of CKD when eGFR <60 mL/min/m ² .	Worsening renal function was associated with increased in-hospital mortality, hospital ength of stay in SAVR patients, but not in TAVR patients	TAVR is safe for patients with CKD. The presence of pre-existing DM and elevated pre-operative serum creatinine appear to confer a greater risk of developing AKI	coperative severe renal disease is a predictor for all-cause 1-year mortality in TAVR patients	(Continues)
	Conclusion by authors	Preoperati not incr nisk of AKI afte	Patients with CKD or ESRD have worse in-hospital outcom after TAVR. AKI is after TAVR. AKI is after the outcom in-hospital mortalit in patients undergoing TAVR	Increasing CKD st leads to an incr nisk of death an RRT. Continuou analysis showe significant diffe in outcomes in all levels of CKD v eGFR <60 mL/	Worsening was asso increaset increaset increaset increaset increaset increaset in SAVR but not i patients	TAVR is safe for p with CKD. The presence of pre DM and elevative pre-operative serum creatinin appear to confr greater risk of developing AKI	Preoperative severe renal disease is a significant predict for all-cause 1-ye mortality in TAVR patients	
	Outcome definition	30-day mortality, cardiac death, stroke, transient neurobgic deficit, AK, RRT, new pacemaker, reoperation	All-cause in-hospital mortality, CVS events, acute MI, stroke, major bleeding, major vascular complications, requirement for pacemaker implantation	Death from any cause, new requirement of RRT, or a composite of both	Transfusion, stroke, AF, pneumonia, new dialysis, worsening renal failure, bleeding, ventilation, ICU, discharge creatinine, length of stay, contrast load	Mortality, MI, vascular complications, overall length of stay	Death from any cause, CVS mortality, major bleeding, stroke, new permanent pacemaker, new dialysis, MI, major vascular complications	
	Mean 5 age) (years)	81.6	81.1	81.96	82.2	81.3	84.5	
	High STS score (%)	٩	۲	Ч	100	61	100	
	Male (%)	44.4	52.3	51.33	88	57	52.4	
	Total population Male (%)	270	41,025	44,778	1,657	118	2,531	
	Exposure group	CKD stage 3 and worse, AKI (elevation of creatinine of 0.3 mg/dL or greater, decrease of GFR of greater than 25%, or the need of RRT)	Patients with CKD were identified using ICD-9-CM codes 35.05 and 35.06	CKD has 5 stages, organized by eGFR (CKD stage 1 = eGFR >90 mL/min/m ² , stage 2 = GFR 60 - 89 mL/min/m ² , stage 3 = eGFR of 30 - 59 mL/min/m ² , stage 4 = GFR of 15 - 29 mL/min/m ² , stage 5 = eGFR <15 mL/min/m ²). Combined stages 1 and 2 serving as a control group	eGFR >60 mL/min, eGFR Hospital based 31-60 mL/min, and eGFR ≤30 mL/min	CKD group (eGFR <60 mL/min/ 1.73 m ²) and no-CKD group (eGFR >60 mL/min/1.73 m ²)	eGFR >60 mL/min, GFR 31-60 mL/min, and GFR ≤ 30 mL/min	
	Exclusion criteria	Patients on chronic hemodialysis	Patients with ESRD	Patients with GFR measurements >130 mL/min/m ² , currently dialysis dependent, and those that received mitral leaflet clip mitral leaflet clip	Irretrievable creatinine levels	Chronic hemodialysis patients	Cannot calculate the GFR due to missing data, post renal transplantation	
	Participant description	All patients underwent transaptical transcatheter aortic valve implantation at the center	All patients age ≥ 18 years who underwent TAVR	Data from the STS/ACC TVT registry from November 2011 through September 2015 on patients undergoing TAVR	Medical records for all consecutive isolated aortic valve replacements at Emory healthcare hospitals	Consecutive patients underwent TAVR	Patients enrolled in the PARTNET trial and continuous access registry and treated with TAVR	
	Setting of study	Hospital based	Hospital based	Hospital based	Hospital based	Hospital based	Hospital based	
	Study design	2013 Prospective F cohort study	2017 Retrospective H cohort study	2017 Retrospective H cohort study	Retrospective cohort study	2015 Retrospective H cohort study	2016 Retrospective H cohort study	
nued)	v of		201	201	2013	201	201	
(Continued)	Country of origin	Germany	USA	USA	NSA	Ä	USA	
TABLE 1	Author	Goebel	Gupta	Hansen	Nguyen	Rahman	Thourani	

E120 WILEY-


σ	
Φ	
_	
-	
~	
\sim	
\sim	
\sim	
\sim	
_	
, ,	
-	
-	
-	
-	
-	
-	
BLE	
BLE	
ABLE	
ABLE	
ABLE	
ABLE	

Conclusion by authors	TAVR with the CoreValve prosthesis does not seem to bear an increased risk for patients with CKD. For surgical high-risk patients with severe AS, a more consideration for TAVR	Classification of CKD stages before TAVR allow risk stratification for early and midterm clinical outcomes. TAVR for patients with CKD stage 4 is still considered challenging because of high mortality rates after the procedure
Mean High STS age Outcome score (%) (years) definition	Renal function, renal replacement therapy, 30-day mortality	Length of hospital stay, mortality, MI, stroke, AKI, need for dialysis at discharge, vascular complications, transfusion, pacemaker implantation
Mean age (years)	44.8	83.5
Mean High STS age score (%) (years	100	100
H H s (%) s		
Total population Male (%)	81.1	48.1
Total populat	199	642
Exposure group	Pre-procedural eGFR s60 mL/min, equivalent to CKD stage ≥3	CKD stage 1 + 2. CKD stage 3a, CKD stage 3b, and CKD stage 4 on the basis of eGFR ≥ 60, 45-59, 30-44, and 15-29 mL/min/ 1.73 m ² , respectively
Exclusion criteria	Patients who died within 24 hr after TAV or patients on chronic HD or in need for pre-interventional RRT	Receiving regular HD before TAVR
Setting Participant of study description	Patients with symptomatic high-grade AS undergoing TAVR with the CoreValve prosthesis	Hospital Consecutive patients based who underwent TAVR
Setting of study	Hospital based	Hospital based
Year Study design	2012 Retrospective I	2013 Prospective 1 cohort study
		201
Country of origin	Germany	France
Author	Wessely	Yamamoto France

Abbreviations: ACC, American College of Cardiology; AF, atrial fibrillation; AKI, acute kidney injury; AS, aortic stenosis; CKD, chronic kidney disease; CVS, cardiovascular; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; HD, hemodialysis; ICD, international classification of disease; ICU, intensive care unit; MI, myocardial infarction; RRT, renal replacement therapy; SAVR, surgical aortic valve replacement; STS, Society for Thoracic Surgeon; TAVR, transcatheter aortic valve replacement; TVT, transcatheter valve therapy; UK, United Kingdom; USA, United States.

E122 WILEY-

	Risk Ratio %	Woigh
(A) Study, CKD stages, year		6Weigh
CKD 3		
Allende. 2014	1.28 (0.89, 1.84)	6.46
Ascenzo 2013	2.96 (0.70, 12.44)	0.96
Dumonteil 2013	1.51 (0.91, 2.51)	4.69
Hansen 2017		9.74
Nguyen 2013 -	0.72 (0.21, 2.44)	1.28
Thourani 2016	0.99 (0.70, 1.39)	6.75
Yamamoto 2013 (CKD 3a)	1.37 (0.67, 2.79)	3.06
Yamamoto 2013 (CKD 3b)	1.82 (0.94, 3.51)	3.41
Subtotal (I-squared = 0.0%, p = 0.553)	0 1.26 (1.13, 1.41)	36.34
CKD 4	1	
Allende. 2014	1.71 (1.21, 2.42)	6.69
Ascenzo 2013	3.45 (0.74, 16.06)	0.85
Dumonteil 2013	1.52 (0.64, 3.59)	2.30
Hansen 2017	1.90 (1.47, 2.44)	8.12
Yamamoto 2013	3.04 (1.43, 6.48)	2.80
Subtotal (I-squared = 0.0% , p = 0.614)	1.89 (1.56, 2.29)	20.75
CKD 5 Allende 2014	1.80 (1.07, 3.03)	4.57
Dumonteil 2013	1.52 (0.64, 3.59)	2.30
Ferro 2017	2.29 (1.17, 4.47)	3.33
Goebel 2013	0.99 (0.40, 2.42)	2.16
Gupta 2017		8.86
Hansen 2017		1.68
Subtotal (I-squared = 38.4%, p = 0.150)	1.93 (1.42, 2.62)	22.90
Nonspecific		
Gobel 2013 (CKD 3-4)	0.99 (0.40, 2.42)	2.16
Gupta 2017 (CKD 3-4)	◆ 1.39 (1.24, 1.55)	10.01
Nguyen 2013 (CKD 4-5)	1.01 (0.11, 9.40)	0.42
Rahman 2015 (CKD 3-5)	→ 3.49 (0.40, 30.32)	0.45
Thourani 2016 (CKD 4-5)	1.74 (1.13, 2.68)	5.54
Wessely 2015 (CKD 3-5)	0.50 (0.16, 1.59)	1.43
Subtotal (I-squared = 6.6%, p = 0.374)	1.39 (1.17, 1.65)	20.00
. Overall (Legisland $= 60.0\%$ $= 0.000$)		100.00
Overall (I-squared = 60.9%, p = 0.000)	• 1.56 (1.34, 1.80)	100.00
NOTE: Weights are from random effects analysis	s	
	1 1	
(B) .1	1 10	
(B) .1 Study, CKD stages, year	1 10	%Weight
(B) Study, CKD stages, year	1 10	%Weight
(B) Study, CKD stages, year CKD 3	1 10 Risk Ratio	
(B) Study, CKD stages, year	1 10	%Weight 23.44
(B) Study, CKD stages, year CKD 3	1 10 Risk Ratio	
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52)	23.44 1.93
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33)	23.44 1.93 11.54
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016	Risk Ratio	23.44 1.93 11.54 17.56
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33)	23.44 1.93 11.54
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455)	Risk Ratio	23.44 1.93 11.54 17.56
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4	Risk Ratio	23.44 1.93 11.54 17.56 54.48
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014	Risk Ratio	23.44 1.93 11.54 17.56 54.48 11.21
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4	Risk Ratio	23.44 1.93 11.54 17.56 54.48
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014	Risk Ratio 1 10 Risk Ratio 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04)	23.44 1.93 11.54 17.56 54.48 11.21
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013	1 10 Risk Ratio 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06)	23.44 1.93 11.54 17.56 54.48 11.21 1.73
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013	1 10 Risk Ratio 1 1 10 1 10 1 10 1 10 1 126 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013	1 10 Risk Ratio 1 1 10 1 10 1 10 1 10 1 126 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5	1 10 Risk Ratio 1 1 10 1 10 Risk Ratio 1 1 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014	1 10 Risk Ratio 1 1 10 1 10 1 10 1 10 1 10 1 10 1 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014	1 10 Risk Ratio 1 1 10 1 10 1 10 1 10 1 10 1 10 1 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558)	1 10 Risk Ratio 4 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558) Nonspecific	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558)	1 10 Risk Ratio 4 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57
 (B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) . CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) . CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558) . Nonspecific Gobel 2013 (CKD 3-4) 	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22) 1.55 (0.42, 5.62)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93 2.42
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558) Nonspecific Gobel 2013 (CKD 3-4) Thourani 2016 (CKD 4-5)	1 10 Risk Ratio 4 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22) 1.55 (0.42, 5.62) 1.60 (0.93, 2.74)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93 2.42 11.81
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558) Nonspecific Gobel 2013 (CKD 3-4)	1 10 Risk Ratio 9 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22) 1.55 (0.42, 5.62)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93 2.42
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558) Nonspecific Gobel 2013 (CKD 3-4) Thourani 2016 (CKD 4-5)	1 10 Risk Ratio 4 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22) 1.55 (0.42, 5.62) 1.60 (0.93, 2.74)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93 2.42 11.81
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0% , p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0% , p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0% , p = 0.558) Nonspecific Gobel 2013 (CKD 3-4) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 0.0% , p = 0.963) Overall (I-squared = 13.2% , p = 0.315)	1 10 Risk Ratio 4 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22) 1.55 (0.42, 5.62) 1.60 (0.93, 2.74) 1.59 (0.97, 2.61) 1.47 (1.20, 1.81)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93 2.42 11.81 14.22
(B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 0.0%, p = 0.455) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 0.0%, p = 0.609) CKD 5 Allende 2014 Dumonteil 2013 Goebel 2013 Subtotal (I-squared = 0.0%, p = 0.558) Nonspecific Gobel 2013 (CKD 3-4) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 0.0%, p = 0.963)	1 10 Risk Ratio 4 1.26 (0.90, 1.77) 2.47 (0.58, 10.52) 1.35 (0.78, 2.33) 0.93 (0.61, 1.41) 1.18 (0.94, 1.49) 1.74 (1.00, 3.04) 3.45 (0.74, 16.06) 1.38 (0.54, 3.53) 1.75 (1.11, 2.77) 1.99 (0.99, 4.00) 3.02 (1.22, 7.45) 4.70 (0.94, 23.55) 2.50 (1.48, 4.22) 1.55 (0.42, 5.62) 1.60 (0.93, 2.74) 1.59 (0.97, 2.61) 1.47 (1.20, 1.81)	23.44 1.93 11.54 17.56 54.48 11.21 1.73 4.43 17.37 7.61 4.75 1.57 13.93 2.42 11.81 14.22



(RR = 1.19, 95% CI: 0.97–1.45, $I^2 = 0.0\%$) (Supporting information Figure S3) as well as 30-day overall vascular complications (RR = 1.06, 95% CI: 0.99–1.14, $I^2 = 0.0\%$) (Supporting information Figure S4) but did not reach statistically significant.

Subgroup analysis of CKD stage 4 increased risk of cerebrovascular accident (RR = 1.89, 95% CI: 1.22–2.94, I^2 = 0.0%) but did not

reach statistically significant in overall CKD when compared to control (RR = 1.19, 95% CI: $0.95-1.50, I^2 = 26.9\%$).

Similar to risk of mortality, risk of 30-day overall bleeding increased with severity of CKD for stages 3, 4, and 5, respectively (RR = 1.19, 1.63, and 2.12) (Figure 4A) as well as 30-day major bleeding (RR = 1.09, 1.12, and 1.86) (Figure 4B).

OKD 3 Allende 2014 1.18 (0.98, 1.42) 22.59 Ascenze 2013 1.18 (0.98, 1.42) 27.69 Coder 2016 1.18 (0.98, 1.42) 27.86 Thourani 2016 1.18 (0.98, 1.42) 27.86 Subtotal (L-squared = 0.0%, p = 0.988) 1.29 (0.98, 1.42) 5.89 I 2.000 (0.10, 0.10) 1.83 (121, 2.21) 15.45 Ascenze 2013 Coder 2016 2.26 (155, 7.27) 2.89 Codor 2016 1.99 (0.81, 2.06) 9.04 1.09 (1.84, 2.43) 30.27 CKD 5 Allende 2014 1.01 (0.31, 3.30) 1.85 1.82 (1.10, 2.39) 11.67 Subtotal (L-squared = 0.0%, p = 0.707) 1.62 (1.10, 2.39) 11.67 1.62 (1.10, 2.39) 11.67 Subtotal (L-squared = 36.2%, p = 0.118) 1.44 (122, 1.70) 100.00 1.07 (0.90, 1.28) 6.77 Subtotal (L-squared = 36.2%, p = 0.118) 1.44 (122, 1.70) 100.00 1.77 (1.98, 2.99) 3.33 Norspecific 1.44 (122, 1.70) 1.00.00 1.67 (1.98, 2.99) 3.33 Thourani 2016 (CKD 4.5) 1.62 (1.10, 2.39) 1.67 (1.98, 2.99) 3.33 Subtotal (L-squared = 56.5%, p = 0.027)	(A) Study, CKD stages, year	Risk Ratio %Weigh
Ascenzo 2013 Coder 2016 Thouran 2016 Subtotal (I-squared = 0.0%, p = 0.988) CKD 4 Alende 2014 Ascenzo 2013 Coder 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Alende 2014 Coder 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Alende 2014 Coder 2016 Subtotal (I-squared = 8.7%, p = 0.334) Nonspecific Thourani 2016 (CKD 4-5) Study CKD stages, year CKD 3 Alende 2014 CKD 3 Alende 2014 CKD 5 Alende 2014 Coder 2016 Subtotal (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) CKD 3 Alende 2014 CKD 4 Alende 2014 CKD 4 Alequared = 50.2%, p = 0.091) CKD 5 Alende 2016 CKD 4 Alequared = 50.5%, p = 0.090) Alef (145, 1.81) 100.00 Alef (145, 1.81) 100.00 Alef (145, 1.81) 100.00 Ale	CKD 3	
Ascenzo 2013 Coder 2016 Thouran 2016 Subtotal (I-squared = 0.0%, p = 0.988) CKD 4 Alende 2014 Ascenzo 2013 Coder 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Alende 2014 Coder 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Alende 2014 Coder 2016 Subtotal (I-squared = 8.7%, p = 0.334) Nonspecific Thourani 2016 (CKD 4-5) Study CKD stages, year CKD 3 Alende 2014 CKD 3 Alende 2014 CKD 5 Alende 2014 Coder 2016 Subtotal (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) CKD 3 Alende 2014 CKD 4 Alende 2014 CKD 4 Alequared = 50.2%, p = 0.091) CKD 5 Alende 2016 CKD 4 Alequared = 50.5%, p = 0.090) Alef (145, 1.81) 100.00 Alef (145, 1.81) 100.00 Alef (145, 1.81) 100.00 Ale	Allende 2014	1.18 (0.98, 1.42) 22.59
Codner 2016 1.12 (0.59, 2.12) 5.59 Thourani 2016 1.24 (0.93, 1.66) 16.23 Subtotal (I-equared = 0.0%, p = 0.986) 1.9 (1.02, 1.39) 47.17 CKD 4 1.63 (1.21, 2.21) 15.45 Alenda 2014 1.83 (1.21, 2.21) 15.45 Codner 2016 2.26 (1.53, 2.33) 12.21 Subtotal (I-equared = 8.7%, p = 0.334) 1.90 (1.48, 2.49) 30.27 . . 1.90 (1.48, 2.49) 30.27 1.90 (1.48, 2.49) 30.27 . <td< td=""><td>Ascenzo 2013</td><td></td></td<>	Ascenzo 2013	
Thourain 2016 1.24 (0.93, 1.66) 16.23 Subtotal (I-squared = 0.0%, p = 0.988) 1.19 (1.02, 1.39) 47.17 CKD 4 1.53 (1.21, 2.21) 15.45 Allende 2014 2.76 (1.05, 7.27) 2.89 Codner 2016 2.26 (1.53, 3.23) 12.12 Subtotal (I-squared = 8.7%, p = 0.334) 1.01 (0.41, 3.30) 1.85 Codner 2016 1.90 (1.48, 2.43) 30.27 Subtotal (I-squared = 0.0%, p = 0.707) 1.91 (1.48, 2.43) 30.27 Nonspecific 1.90 (0.41, 2.06) 9.04 Thourain 2016 (CKD 4-5) 1.82 (1.10, 2.39) 11.67 Subtotal (I-squared = 36.2%, p = 0.118) 1.44 (1.22, 1.70) 100.00 NOTE: Weights are from random effects analysis 1.07 (0.90, 1.28) 6.77 Study, CKD stages, year Risk Ratio %Weigh CKD 3 1.97 (0.93, 4.19) 2.72 Cadrer 2016 1.92 (1.10, 2.39) 1.67 Derrigo 2015 1.92 (1.21, 1.85) 6.41 Hannan 2016 (CKD 3a) 1.97 (0.93, 4.19) 2.77 Subtotal (I-squared = 50.2%, p = 0.091) 1.82 (1.10, 2.89) 1.83 (1.11, 1.81) CKD 5 <t< td=""><td></td><td></td></t<>		
Subtotal (I-squared = 0.0%, p = 0.988) I 19 (102, 139) 47.17 CKD 4 Alende 2014 Codner 2016 Subtotal (I-squared = 8.7%, p = 0.334) I 22 (21, 53, 323) 12.12 Subtotal (I-squared = 8.7%, p = 0.334) I 29 (0.81, 2.06) 9.04 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) I 28 (0.81, 1.93) 10.80 I 10 (0.31, 3.30) 1.85 Subtotal (I-squared = 0.0%, p = 0.707) I 28 (0.81, 1.93) 10.80 I 10 (0.31, 3.30) 1.85 Subtotal (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) Study, CKD stages, year Risk Ratio %Weigh CKD 3 Allende 2014 Ascence 2013 Codner 2016 DV raige 2015 Hansen 2017 Thourani 2016 CKD 5 Allende 2014 Ascence 2013 Codner 2016 DV raige 2015 Hansen 2017 CKD 5 Allende 2014 Ascence 2013 CKD 5 Allende 2014 As		
CKD 4 1.63 (1.21, 2.21) 15.45 Allende 2014 2.76 (1.05, 7.27) 2.69 Subtotal (I-squared = 8.7%, p = 0.334) 2.26 (1.05, 7.27) 2.69 CKD 5 1.90 (1.48, 2.43) 30.27 CKD 5 1.29 (0.81, 2.06) 9.04 Codner 2016 1.29 (0.81, 2.06) 9.04 Subtotal (I-squared = 0.0%, p = 0.707) 1.25 (0.81, 1.98) 10.90 Nonspecific 1.07 (0.31, 3.30) 1.87 Thourani 2016 (CKD 4-5) 1.62 (1.10, 2.39) 11.67 Subtotal (I-squared = 36.2%, p = 0.118) 1.44 (1.22, 1.70) 100.00 NOTE: Weights are from random effects analysis 107 109, 1.28 6.77 Study, CKD stages, year Risk Ratio % Weight 7.7 CKD 3 1.97 (0.39, 1.49) 6.77 1.52 (1.10, 1.81) 5.44 Yamamoto 2013 (CKD 3a) 1.32 (1.02, 2.89) 3.33 1.52 (1.51, 1.85) 6.64 Yamamoto 2013 (CKD 3a) 1.37 (1.09, 2.89) 4.15 3.34 3.34 3.34 3.34 3.34 3.34 3.35 1.52 (1.02, 2.39) 3.35 1.52 (1.02, 2.39) 3.33 1.52 (1.01, 2.39)		
Allende 2014 Ascenzo 2013 Cother 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Allende 2014 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) Nonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) CKD 5 Allende 2014 Codner 2016 Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 CKD 3 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 5 Hansen 2017 Study CKD Stages, year CKD 4 Allende 2014 Ascenzo 2013 Codiner 2016 CKD 5 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.027) CKD 5 Allende 2014 Ascenzo 2013 Codiner 2016 CMD 4 Allende 2014 Ascenzo 2013 Codiner 2016 CMD 4 Allende 2014 Ascenzo 2013 Codiner 2016 CMD 5 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.027) CKD 5 Allende 2014 Ascenzo 2013 CCD 5 Allende 2014 Ascenzo 2013 Codiner 2016 Derrigo 2015 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.027) CKD 5 Allende 2014 Ascenzo 2013 CCD 5 Allende 2014 Ascenzo 2013 CCD 5 Allende 2014 Codiner 2016 Derrigo 2015 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.027) CKD 5 Allende 2014 Codiner 2016 Derrigo 2015 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.026) NOTE: Weights are from random effects analysis Derrigo 2015 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.026) NOTE: Weights are from random effects analysis CVC 15 Allende 2014 Codiner 2016 Derrigo 2015 Hansen 2017 Studytotal (I-squared = 56.5%, p = 0.026) CVC 15 Allende 2014 Codiner 2016 Derrigo 2015 Frain 2017 Studytotal (I-squared = 56.5%, p = 0.026) CVC 15 Allende 2014 Codiner 2016 Derrigo 2015 Frain 2017 Studytotal (I-squared = 56.5%, p = 0.026) CVC 15 Allende 2014 Codiner 2016 Derrigo 2015 Frain 2017 Studytotal (I-squared = 60.3%, p = 0.020) CVC 15	Subtotal (I-squared = 0.0%, p = 0.988)	1.19 (1.02, 1.39) 47.17
Ascenzo 2013 Codner 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Alende 2014 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) Nonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) .1 Study, CKD stages, year CKD 3 Alende 2014 Codner 2016 Codner 2016 Codn	CKD 4	
Codner 2016 Subtotal (I-squared = 8.7%, p = 0.334) CKD 5 Allende 2014 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) Nonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 9.6.%, p = 0.118) NOTE: Weights are from random effects analysis B) .1 Study, CKD stages, year CKD 3 Allende 2014 Codner 2016 Study, CKD stages, year CKD 3 Allende 2014 Allende 2015 Harsen 2017 Thourani 2015 (CKD 38) Subtotal (I-squared = 58.%, p = 0.027) CKD 5 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 CKD 5 Allende 2015 Ferro 2017 Thourani 2016 (CKD 3-5) Thourani 2017 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 4-5) Subtotal (I-squared = 80.3%, p = 0.005) Allende 2016 CKD 4-5) Thourani 2016 (CKD 3-5) Thour	Allende 2014	1.63 (1.21, 2.21) 15.45
Subtotal (I-squared = 8.7%, p = 0.334) I 190 (1.48, 2.43) 30.27 CKD 5 Allende 2014 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) I 29 (0.81, 2.09) 9.04 1.01 (0.31, 3.30) 1.85 I 25 (0.81, 1.93) 10.90 I 1 10 Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Thourant 2018 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 56.9%, p = 0.027) I CKD 4 Allende 2014 Ascenzo 2013 CCM 5 Allende 2014 Ascenzo 2013 CCM 4 Allende 2014 Ascenzo 2013 CCM 5 Allende 2014 CCM 5 Allende 2014 Codner 2016 D'errigo 2015 Hansen 2017 Hansen 2017	Ascenzo 2013	 2.76 (1.05, 7.27) 2.69
CKD 5 Allende 2014 1.29 (0.81, 2.06) 9.04 Codner 2016 1.01 (0.31, 3.30) 1.85 Subtolal (I-squared = 0.0%, p = 0.707) 1.25 (0.81, 1.93) 10.90 . . 1.25 (0.81, 1.93) 10.90 . . 1.62 (1.10, 2.39) 11.67 Subtolal (I-squared = 36, 2%, p = 0.118) 1.44 (1.22, 1.70) 100.00 NOTE: Weights are from random effects analysis 1.07 (0.90, 1.28) 6.77 B) .1 10 Study, CKD stages, year Risk Ratio %Weigh CKD 3 1.07 (0.90, 1.28) 6.77 Alende 2014	Codner 2016	2.22 (1.53, 3.23) 12.12
Allende 2014 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) inonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = .%, p = .) Overall (I-squared = .%, p = .) Coder 2016 Subtotal (I-squared = .%, p = .) Coder 2016 Subtotal (I-squared = .%, p = .) Coder 2016 Subtotal (I-squared = .%, p = .) Coder 2016 Vamamoto 2013 (CKD 3a) Vamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.%, p = 0.091) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 Derrigo 2015 Allende 2014 Ascenzo 2013 Codner 2016 CKD 3 Allende 2014 Ascenzo 2013 Codner 2016 Derrigo 2015 Allende 2014 Ascenzo 2013 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Tourani 2016 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 56.5%, p = 0.056) Derrigo 2015 Ferro 2017 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016 Codner 2016 Derrigo 2015 Ferro 2017 Codner 2016	Subtotal (I-squared = 8.7%, p = 0.334)	1.90 (1.48, 2.43) 30.27
Allende 2014 Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) incospecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) CKD 3 Allende 2014 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 4-5) Thourani 2016 (CKD 4-5) Thourani 2016 (CKD 4-5) Thourani 2016 (CKD 4-5) Thourani 2016 (CKD 4-5) Thourani	CKD 5	
Codner 2016 Subtotal (I-squared = 0.0%, p = 0.707) Nonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 36, 2%, p = .) Overail (I-squared = 36, 2%, p = 0.118) NOTE: Weights are from random effects analysis B) 1 Study, CKD stages, year Codner 2016 CKD 3 Allende 2014 Ascerzo 2013 Codner 2016 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 CKD 5 Allende 2014 Ascerzo 2013 Codner 2016 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 CKD 5 Allende 2014 Ascerzo 2013 Codner 2016 Chergio 2015 Hansen 2017 CKD 4 Allende 2014 Ascerzo 2013 Codner 2016 Codner 2016 Codner 2016 Codner 2016 Codner 2016 Codner 2016 Codner 2017 Hansen 2017 CKD 5 Allende 2014 Ascerzo 2013 CKD 5 Allende 2014 Ascerzo 2013 Allende 2014 Allende 2014 As		1 29 (0 81 2 06) 9 04
Subtotal (I-squared = 0.0%, p = 0.707) Nonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 36.2%, p = .) Overall (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Codner 2016 CMD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2015 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Ratimar 2017 Nonspecific Ratimar 2015 CKD 4 Nonspecific Ratimar 2015 CKD 4 Nonspecific Ratimar 2015 Thourani 2016 (CKD 4-5) Thourani 2016 (CKD 4-5)		
Nonspecific Thourani 2016 (CKD 4-5) Subtotal (I-squared = 36, 2%, p = 0, 118) NOTE: Weights are from random effects analysis B) Study, CKD stages, year Risk Ratio %Weigh CKD 3 Alende 2014 Ascenzo 2013 Codner 2016 CKD 4 Allende 2014 Ascenzo 2013 (CKD 3a) Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3a) CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2015 Ferro 2017 Hansen 2019 Hansen 2017 Hansen 2017 Hanse		
Thourani 2016 (CKD 4-5) Subtotal (I-squared = .%, p = .) i. Overall (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) 1.1 1.44 (1.22, 1.70) 100.00 NOTE: Weights are from random effects analysis B) 1.44 (1.22, 1.70) 100.00 NOTE: Weights are from random effects analysis CKD 3 Allende 2014 Ascenzo 2013 Codner 2016 CKD 4 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 3 D'errigo 2015 Hansen 2017 CKD 4 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 CKD 5 Allende 2014 Ccdner 2016 D'errigo 2015 Hansen 2017 CKD 6 Allende 2014 Ccdner 2016 D'errigo 2015 Hansen 2017 CKD 5 Allende 2014 Ccdner 2016 D'errigo 2015 Hansen 2017 CKD 5 Allende 2014 Ccdner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.091) CKD 5 Allende 2014 Ccdner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 CKD 5 ChD 3- Subtotal (I-squared = 56.5%, p = 0.056) Norspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 3-5) Thourani 2	Subtotal (I-squared = 0.0%, p = 0.707)	1.25 (0.81, 1.93) 10.90
Subtotal (I-squared = .%, p = .) Overall (I-squared = 36.2%, p = 0.118) NOTE: Weights are from random effects analysis B) .1 Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 4 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 Ascenzo 2013 CKD 5 Allende 2014 CKD 5 CKD 5 Allende 2014 CKD 4-5) Yumamoto 2013 (CKD 3-5) Thourani 2016 (CKD 3-5) Thourani	Nonspecific	
Overall (I-squared = 36.2%, p = 0.118) 1.44 (1.22, 1.70) 100.00 NOTE: Weights are from random effects analysis 10 B) .1 10 Study, CKD stages, year Risk Ratio %Weigh CKD 3 1.07 (0.90, 1.28) 6.77 Allende 2014 1.07 (0.90, 1.28) 6.77 Ascenzo 2013 1.66 (0.95, 2.90) 3.33 D'errigo 2015 1.52 (1.25, 1.85) 6.66 Hansen 2017 1.71 (1.09, 2.68) 4.15 Subtotal (I-squared = 55.8%, p = 0.027) 1.28 (1.11, 1.41) 5.64 Codner 2016 1.27 (1.18, 1.38) 7.45 Codner 2016 1.28 (1.11, 1.41) 5.64 Allende 2014 3.33 (1.17, 2.528) 3.33 D'errigo 2015 1.72 (1.33, 2.22) 6.03 Codner 2016 1.72 (1.33, 2.22) 6.03 D'errigo 2015 1.24 (0.65, 2.36) 2.80 Hansen 2017 2.36 (1.10, 3.41) 5.99 Subtotal (I-squared = 56.5%, p = 0.056) 1.24 (0.65, 2.36) 2.80 Nonspecific Rahman 2015 (CKD 3-5) 1.24 (0.65, 2.36) 2.80 Hansen 2017	Thourani 2016 (CKD 4-5)	1.62 (1.10, 2.39) 11.67
NOTE: Weights are from random effects analysis B) .1 10 Study, CKD stages, year Risk Ratio %Weigh CKD 3 Allende 2014 1.07 (0.90, 1.28) 6.77 Allende 2014 1.07 (0.90, 1.28) 6.77 Allende 2015 1.37 (0.93, 4.19) 2.27 Codner 2016 1.66 (0.95, 2.90) 3.33 D'errigo 2015 1.24 (1.8, 1.38) 7.45 Hansen 2017 1.27 (1.18, 1.38) 7.45 Subtotal (I-squared = 55.8%, p = 0.027) Allende 2014 <	Subtotal (I-squared = .%, p = .)	1.62 (1.10, 2.39) 11.67
B) .1 1 10 Study, CKD stages, year Risk Ratio %Weigh CKD 3 Allende 2014 Ascenzo 2013 Codner 2016 Hansen 2017 CKD 4 Allende 2014 Allende 2014 Ascenzo 2013 Codner 2016 Hansen 2017 CKD 4 Allende 2014 Allende 2014 Ascenzo 2013 Codner 2016 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.091) CKD 5 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.096) Norspecific Rahma 2015 (CKD 3-5) Thourani 2016 (CKD	Overall (I-squared = 36.2%, p = 0.118)	1.44 (1.22, 1.70) 100.00
Dystantial Risk Ratio %Weigh CKD 3 Allende 2014 1.07 (0.90, 1.28) 6.77 Ascenzo 2013 1.97 (0.93, 4.19) 2.27 Codner 2016 1.66 (0.95, 2.90) 3.33 D'errigo 2015 1.52 (1.25, 1.85) 6.56 Hansen 2017 1.27 (1.18, 1.38) 7.45 Thourani 2016 1.04 (0.88, 1.23) 6.81 Yamamoto 2013 (CKD 3a) 1.34 (0.83, 2.16) 3.94 Yamamoto 2013 (CKD 3b) 1.34 (0.83, 2.16) 3.94 Subtotal (I-squared = 55.8%, p = 0.027) 1.28 (1.13, 1.45) 41.29 CKD 4 1.35 (1.01, 1.81) 5.64 Allende 2014 1.35 (1.01, 1.81) 5.64 Ascenzo 2013 2.02 (1.57, 2.60) 3.33 D'errigo 2015 1.82 (1.49, 2.23) 2.394 Allende 2014 1.35 (1.01, 1.81) 5.64 Allende 2014 CKD 5 Allende 2014 D'errigo 2015	NOTE: Weights are from random effects analysis	
Study, CKD stages, year Risk Ratio %Weigh CKD 3 Allende 2014 Ascenzo 2013 1.07 (0.90, 1.28) 6.77 Codner 2016 1.06 (0.95, 2.90) 3.33 Derrigo 2015 1.52 (1.25, 1.85) 6.56 Hansen 2017 1.04 (0.88, 1.23) 6.81 Yamamoto 2013 (CKD 3a) 1.34 (0.83, 2.16) 3.94 Yamamoto 2013 (CKD 3b) 1.34 (0.83, 2.16) 3.94 Subtotal (I-squared = 55.8%, p = 0.027) 1.28 (1.13, 1.45) 4.15 . CXD 4 1.35 (1.01, 1.81) 5.64 Ascenzo 2013 Codner 2016 1.04 (0.88, 1.22) 6.33 D'errigo 2015 1.35 (1.01, 1.81) 5.64 Hansen 2017 1.82 (1.49, 2.23) 2.394 1.72 (1.33, 2.22) 6.03 Subtotal (I-squared = 56.5%, p = 0.056) 2.25 (0.93, 5.44) 1.80 2.87 (2.04, 4.03) 5.16 Ferro 2017 1.82 (1.49, 2.23) 2.94 1.24 (0.85, 2.36) 2.80 Hansen 2017 1.24 (0.85, 2.36) 2.80 1.83 (1.22, 2.74) 1.83 (1.22, 2.74) 1.28 (1.33, 4.00) 3.60 Subtotal (I-squared = 56.5%, p = 0.056) 1.24 (0.85, 2.36	B) .1 1	1 10
CKD 3 Allende 2014 1.07 (0.90, 1.28) 6.77 Ascenzo 2013 1.07 (0.90, 1.28) 6.77 Codner 2016 1.97 (0.93, 4.19) 2.27 Dorrigo 2015 1.52 (1.25, 1.85) 6.66 Hansen 2017 1.04 (0.88, 1.23) 6.81 Yamamoto 2013 (CKD 3a) 1.34 (0.83, 2.16) 3.64 Yamamoto 2013 (CKD 3b) 1.34 (0.83, 2.16) 3.64 Subtotal (I-squared = 55.8%, p = 0.027) 1.28 (1.13, 1.45) 41.29 . CKD 4 1.35 (1.01, 1.81) 5.64 Allende 2014 3.01 (1.72, 5.26) 3.33 Derrigo 2015 1.35 (1.02, 1.84) 1.96 Hansen 2017 1.75 (1.50, 2.03) 6.97 Subtotal (I-squared = 50.2%, p = 0.091) 1.75 (1.50, 2.03) 6.97 . CKD 5 1.172 (1.33, 2.22) 6.03 Allende 2014 2.25 (0.93, 5.44) 1.80 Derrigo 2015 2.46 (1.90, 3.18) 5.99 Allende 2014 2.26 (0.32, 5.5%, p = 0.056) 2.12 (1.63, 2.75) 2.194 Nonspecific Rahman 2015 (CKD 3-5) 1.24 (0.85, 2.36) 2.80 Thourani 2016 (CKD 4		Risk Ratio %Weigh
Allende 2014 Ascenzo 2013 Codner 2016 Hansen 2017 Thourani 2016 Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	СКРЗ	
Ascenzo 2013 Codner 2016 Hansen 2017 Thourani 2016 Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 Lass (1.01, 1.81) Codner 2016 Allende 2014 Ascenzo 2013 Codner 2016 Codner 2016 D'errigo 2015 Allende 2014 Codner 2016 Codner 2016 D'errigo 2015 Allende 2014 Codner 2016 D'errigo 2015 Allende 2014 Codner 2016 D'errigo 2015 Allende 2014 Codner 2016 D'errigo 2015 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.096) Nonspecific Rahman 2017 (CKD 3-5) Thourani 2016 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		1.07 (0.90, 1.28) 6.77
Codner 2016 D'errigo 2015 Hansen 2017 Thourani 2016 Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Ascenzo 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		
Hansen 2017 Thourani 2016 Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.091) Nonspecific Rahman 2017 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	Codner 2016	
Thourani 2016 Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2017 (CKD 3-5) Thourani 2016 (CKD 3-5) Thourani 2017 (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	D'errigo 2015	1.52 (1.25, 1.85) 6.56
Yamamoto 2013 (CKD 3a) Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	Hansen 2017 🔶 🔸	1.27 (1.18, 1.38) 7.45
Yamamoto 2013 (CKD 3b) Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	——————————————————————————————————————	
Subtotal (I-squared = 55.8%, p = 0.027) CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2013 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		,
CKD 4 Allende 2014 Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2% , p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5% , p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0% , p = 0.082) Overall (I-squared = 80.3% , p = 0.000) NOTE: Weights are from random effects analysis		
Allende 2014 1.35 (1.01, 1.81) 5.64 Ascenzo 2013 2.02 (1.57, 2.60) 3.01 (1.72, 5.26) 3.33 D'errigo 2015 2.02 (1.57, 2.60) 6.04 Hansen 2017 1.75 (1.50, 2.03) 6.97 Subtotal (I-squared = 50.2%, p = 0.091) 1.72 (1.33, 2.22) 6.03 . 1.72 (1.33, 2.22) 6.03 Codner 2016 2.25 (0.93, 5.44) 1.80 D'errigo 2015 2.87 (2.04, 4.03) 5.16 Ferro 2017 1.32 (0.71, 2.45) 2.96 Subtotal (I-squared = 56.5%, p = 0.056) 2.12 (1.63, 2.75) 2.194 Nonspecific 1.24 (0.65, 2.36) 2.80 Rahman 2015 (CKD 3-5) 1.66 (1.34, 2.06) 6.43 Yamamoto 2013 (CKD 4-5) 1.66 (1.45, 1.91) 100.00 NOTE: Weights are from random effects analysis . . .	Subtotal (I-squared = 55.8%, p = 0.027)	1.28 (1.13, 1.45) 41.29
Ascenzo 2013 Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2% , p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5% , p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0% , p = 0.082) Overall (I-squared = 80.3% , p = 0.000) NOTE: Weights are from random effects analysis	CKD 4	
Codner 2016 D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		
D'errigo 2015 Hansen 2017 Subtotal (I-squared = 50.2% , p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5% , p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0% , p = 0.082) Overall (I-squared = 80.3% , p = 0.000) NOTE: Weights are from random effects analysis	I I	
Hansen 2017 Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		
Subtotal (I-squared = 50.2%, p = 0.091) CKD 5 Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	°	
Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		
Allende 2014 Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) · Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) · Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	CKD 5	
Codner 2016 D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		1.72 (1.33, 2.22) 6.03
D'errigo 2015 Ferro 2017 Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2015 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		
Hansen 2017 Subtotal (I-squared = 56.5%, p = 0.056) Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Yamamoto 2013 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis		
Subtotal (I-squared = 56.5%, p = 0.056) 2.12 (1.63, 2.75) 21.94 . Nonspecific 1.24 (0.65, 2.36) 2.80 Rahman 2015 (CKD 3-5) 1.66 (1.34, 2.06) 6.43 Yamamoto 2013 (CKD 4-5) 2.91 (1.73, 4.90) 3.60 Subtotal (I-squared = 60.0%, p = 0.082) 1.83 (1.22, 2.74) 12.83 . Overall (I-squared = 80.3%, p = 0.000) 1.66 (1.45, 1.91) 100.00 NOTE: Weights are from random effects analysis 1.66 (1.45, 1.91) 100.00	Ferro 2017	◆ 2.46 (1.90, 3.18) 5.99
Nonspecific Rahman 2015 (CKD 3-5) Thourani 2016 (CKD 4-5) Yamamoto 2013 (CKD 4-5) Subtotal (I-squared = 60.0%, p = 0.082) Overall (I-squared = 80.3%, p = 0.000) NOTE: Weights are from random effects analysis	Hansen 2017	1.32 (0.71, 2.45) 2.96
Rahman 2015 (CKD 3-5) 1.24 (0.65, 2.36) 2.80 Thourani 2016 (CKD 4-5) 1.66 (1.34, 2.06) 6.43 Yamamoto 2013 (CKD 4-5) 2.91 (1.73, 4.90) 3.60 Subtotal (I-squared = 60.0%, p = 0.082) 1.83 (1.22, 2.74) 12.83 Overall (I-squared = 80.3%, p = 0.000) 1.66 (1.45, 1.91) 100.00 NOTE: Weights are from random effects analysis 1 1	Subtotal (I-squared = 56.5%, p = 0.056)	> 2.12 (1.63, 2.75) 21.94
Thourani 2016 (CKD 4-5) 1.66 (1.34, 2.06) 6.43 Yamamoto 2013 (CKD 4-5) 2.91 (1.73, 4.90) 3.60 Subtotal (I-squared = 60.0%, p = 0.082) 1.83 (1.22, 2.74) 12.83 . . 1.66 (1.45, 1.91) 100.00 NOTE: Weights are from radom effects analysis 1 1.66 (1.45, 1.91) 100.00		
Yamamoto 2013 (CKD 4-5) 2.91 (1.73, 4.90) 3.60 Subtotal (I-squared = 60.0%, p = 0.082) 1.83 (1.22, 2.74) 12.83 Overall (I-squared = 80.3%, p = 0.000) 1.66 (1.45, 1.91) 100.00 NOTE: Weights are from radom effects analysis 1 1		
Subtotal (I-squared = 60.0%, p = 0.082) 1.83 (1.22, 2.74) 12.83 Overall (I-squared = 80.3%, p = 0.000) . 1.66 (1.45, 1.91) 100.00 NOTE: Weights are from random effects analysis . . .		
NOTE: Weights are from random effects analysis		
NOTE: Weights are from random effects analysis	Overall (I-squared = 80.3%, p = 0.000)	1.66 (1.45, 1.91) 100.00
		,
	1 I .1 1	

FIGURE 3 Forest plot of long-term cardiovascular mortality (A) and long-term overall mortality (B) according to stage of CKD [Color figure can be viewed at wileyonlinelibrary.com]

Meta-regression was performed in 30-day overall mortality, long-term overall mortality, 30-day pacemaker implantation, and overall bleeding. Stages of CKD were significant sources of heterogeneity for 30-day overall mortality (P = 0.024), long-term overall mortality (P = 0.001), and overall bleeding (P = 0.021). As shown in subgroup analysis in Figure 2A, heterogeneity of 30-day overall mortality analysis decreased to 0%, 0%, and 38.4% in CKD stages 3, 4, and 5 subgroups, respectively. Heterogeneity of long-term overall mortality also decreased to 55.8%, 50.2%, and 56.5% in CKD stages 3, 4, and 5 subgroup, respectively (Figure 3B). However, stages of CKD and high-risk preoperative evaluation were not significant sources of heterogeneity of 30-day pacemaker implantation (P = 0.246 and P = 0.355, respectively). According to sensitivity analysis, no study was found to be a source of heterogeneity in 30-day major bleeding, 30-day overall mortality, and long-term overall mortality.

E124 WILEY

(A)	Study, CKD stages, year	Risk Ratio %	Weigh
	CKD 3		
	Allende 2014	1.03 (0.72, 1.47)	8.10
	Ascenzo 2013	0.70 (0.30, 1.65)	4.31
	Codner 2016	1.66 (0.75, 3.69)	4.65
	Dumonteil 2013	0.77 (0.59, 1.00)	8.84
	Nguyen 2013	2.29 (0.21, 24.94)	0.89
	Thourani 2016	2.25 (1.54, 3.29)	7.90
	Subtotal (I-squared = 78.5%, p = 0.000)	1.19 (0.75, 1.89)	34.68
	CKD 4		
	Allende 2014	2.39 (1.40, 4.08)	6.58
	Ascenzo 2013	0.99 (0.36, 2.67)	3.59
	Codner 2016	5.19 (2.43, 11.09)	4.90
	Dumonteil 2013	0.57 (0.32, 1.04)	6.06
	Subtotal (I-squared = 87.3%, p = 0.000)	1.63 (0.62, 4.31)	21.12
	CKD 5		
	Allende 2014	2.15 (1.49, 3.11)	7.99
	Codner 2016	7.90 (2.76, 22.60)	3.34
	Dumonteil 2013	1.00 (0.54, 1.87)	5.85
	Gupta 2017	2.13 (1.85, 2.45)	9.61
	Subtotal (I-squared = 74.0%, p = 0.009)	2.12 (1.39, 3.23)	26.81
	Nonspecific		
	Gupta 2017 (CKD 3-4)	1.35 (1.27, 1.44)	9.87
	Nguyen 2013 (CKD 4-5)	3.46 (0.12, 100.29)	
	Thourani 2016 (CKD 4-5)	2.64 (1.63, 4.26)	7.05
	Subtotal (I-squared = 73.9%, p = 0.022)	1.83 (1.00, 3.34)	17.39
	Overall (I-squared = 86.0%, p = 0.000)	1.60 (1.26, 2.02)	100.00
	NOTE: Weights are from random effects analysis		
(8)			
(B)	.1 1 10		
(D)	.1 1 10 Study, CKD stages, year	Risk Ratio %	%Weigh
(0)		Risk Ratio %	%Weigh
(U)	Study, CKD stages, year		
(0)	Study, CKD stages, year CKD 3 Allende 2014	1.03 (0.72, 1.47)	9.51
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65)	9.51 4.78
(0)	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00)	9.51 4.78 10.49
(0)	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29)	9.51 4.78 10.49 9.24
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00)	9.51 4.78 10.49 9.24
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29)	9.51 4.78 10.49 9.24
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29)	9.51 4.78 10.49 9.24 34.01
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08)	9.51 4.78 10.49 9.24 34.01 7.55
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67)	9.51 4.78 10.49 9.24 34.01 7.55 3.94
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67)	9.51 4.78 10.49 9.24 34.01 7.55 3.94
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Gupta 2017	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Subtotal (I-squared = 62.8%, p = 0.068)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific Gupta 2017 (CKD 3-4)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58) 1.35 (1.27, 1.44)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56 11.91
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Gupta 2017 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific Gupta 2017 (CKD 3-4) Thourani 2016 (CKD 4-5)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58) 1.35 (1.27, 1.44) 2.64 (1.63, 4.26)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56 11.91 8.14
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific Gupta 2017 (CKD 3-4)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58) 1.35 (1.27, 1.44)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56 11.91
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific Gupta 2017 (CKD 3-4) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 86.4%, p = 0.007)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58) 1.35 (1.27, 1.44) 2.64 (1.63, 4.26) 1.81 (0.94, 3.46)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56 11.91 8.14 20.05
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Gupta 2017 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific Gupta 2017 (CKD 3-4) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 86.4%, p = 0.007) Overall (I-squared = 88.2%, p = 0.000)	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58) 1.35 (1.27, 1.44) 2.64 (1.63, 4.26)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56 11.91 8.14 20.05
	Study, CKD stages, year CKD 3 Allende 2014 Ascenzo 2013 Dumonteil 2013 Thourani 2016 Subtotal (I-squared = 86.2%, p = 0.000) CKD 4 Allende 2014 Ascenzo 2013 Dumonteil 2013 Subtotal (I-squared = 83.8%, p = 0.002) CKD 5 Allende 2014 Dumonteil 2013 Gupta 2017 Subtotal (I-squared = 62.8%, p = 0.068) Nonspecific Gupta 2017 (CKD 3-4) Thourani 2016 (CKD 4-5) Subtotal (I-squared = 86.4%, p = 0.007) Overall (I-squared = 88.2%, p = 0.000) NOTE: Weights are from random effects analysis	1.03 (0.72, 1.47) 0.70 (0.30, 1.65) 0.77 (0.59, 1.00) 2.25 (1.54, 3.29) 1.09 (0.64, 1.87) 2.39 (1.40, 4.08) 0.99 (0.36, 2.67) 0.57 (0.32, 1.04) 1.12 (0.42, 2.98) 2.15 (1.49, 3.11) 1.00 (0.54, 1.87) 2.13 (1.85, 2.45) 1.86 (1.34, 2.58) 1.35 (1.27, 1.44) 2.64 (1.63, 4.26) 1.81 (0.94, 3.46)	9.51 4.78 10.49 9.24 34.01 7.55 3.94 6.90 18.38 9.37 6.64 11.55 27.56 11.91 8.14 20.05

FIGURE 4 Forest plot of 30-day overall bleeding increased with severity of CKD (A) as well as 30-day major bleeding (B) [Color figure can be viewed at wileyonlinelibrary.com]

3.3 | Quality assessment of included studies

Quality of each study was evaluated by two independent authors (PC, WV). The Newcastle-Ottawa scale (0–9) was used to evaluate included studies on three domains: selection, comparability, and outcomes. Higher scores represent higher study quality. The score of each study ranged from 7 to 9 which reflected high quality (Supporting information

Table S1). Intra-study risks of bias of included studies are also described in supplement Table 2.

Funnel plots of long-term overall mortality, long-term cardiovascular mortality, 30-day overall mortality, and 30-day cardiovascular mortality are shown in Figure 5. Funnel plots were symmetric for long-term cardiovascular mortality and 30-day mortality. However, funnel plots were asymmetric for long-term overall mortality and




FIGURE 5 Funnel plots of long-term overall mortality (A), long-term cardiovascular mortality (B), 30-day mortality (C), and 30-day cardiovascular mortality (D) [Color figure can be viewed at wileyonlinelibrary.com]

30-day cardiovascular mortality. By Egger's test, there was significant publication bias regarding long-term overall mortality (P = 0.019) and 30-day cardiovascular mortality (P = 0.006). Funnel plots for 30-day cerebrovascular accident, 30-day pacemaker implantation, 30-day major bleeding, 30-day overall bleeding, and 30-day vascular complications were symmetric (not shown).

4 DISCUSSION

To date, there is limited evidence regarding the association between varying CKD stages and outcomes in patients undergoing TAVR. Our study is the first meta-analysis to address the association between TAVR complications and CKD stages.

Several comorbidities are known to be associated with poor outcomes in patients who receive TAVR. According to the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry, which was conducted in 1,038 patients, CKD was among the strongest independent predictors of 30-day mortality in patients undergoing TAVR.¹⁵ A meta-analysis published in 2018¹⁶ demonstrated an association between advanced CKD, including stages 4 and 5, and higher mortality in high-risk patients undergoing TAVR. However, this study did not demonstrate association between early and advanced stages of CKD and outcomes. Moreover, several studies that were included in that meta-analysis used CKD stage 4, instead of a normal kidney function control, as a control compared to CKD stage 5.17,18 Therefore, selection bias of cases and controls was, in our opinion, a major limitation in the previous meta-analysis.

Previous work from Hansen et al. reported significantly increased mortality in stage 3 CKD patients who underwent TAVR.¹⁹ However, most studies conducted prior to Hansen et al.²⁰⁻²⁵ found this association insignificant. The association between stage 4 or 5 CKD and increased mortality was reported as significant in later studies.^{19,20,25-28} However, several studies did not report significant association between CKD and risk of mortality in TAVR patients.²⁹⁻³¹ Our meta-analysis demonstrated the association between CKD and 30-day overall mortality, 30-day cardiovascular mortality, long-term cardiovascular mortality, and long-term overall mortality. In metaregression, stages of CKD also showed to be a significant source of heterogeneity thus confirming the significant correlation between the progression of stages of CKD and 30-day overall mortality, overall bleeding, and long-term overall mortality.

CKD is an established risk factor for stroke.^{32,33} Our study showed that CKD stage 4 was associated with increased 30-day cerebrovascular accidents. Nonetheless, the association was not significant in CKD stage 3 and stage 4 patients due to lack of power in included studies since there were a limited number of included studies that reported the incidence of stroke.

Several mechanisms lead to bleeding tendency in CKD patients. Platelet dysfunction progresses as CKD advances. The mechanisms are multifactorial including uremic toxins, anemia, and increased nitric oxide.³⁴ Our study revealed that CKD progression was associated with increased 30-day major bleeding. The association, however, was insignificant in CKD stages 3 and 4. This could be attributed to heterogeneity among studies and underpower.

5 | LIMITATIONS

E126 WILEY

Our meta-analysis is not without limitations. First, included studies were prospective and retrospective cohorts that were observational in nature. Hence, they were subject to confounders; however, a randomized-controlled trial would be impractical. Second, certain outcomes reported in the studies varied slightly in their definitions and durations. Random-effect modeling was, therefore, used for the meta-analysis. Third, the included studies were conducted mostly in Caucasian populations.

6 | CONCLUSION

Stage of CKD prior to procedure positively correlated with overall bleeding complication, 30-day mortality, and long-term overall mortality in patients undergoing TAVR. The presence of CKD, from early to advanced stages, provides prognostic information that should be taken into account when considering a patient for TAVR.

CONFLICT OF INTEREST

None to declare.

ORCID

Pattara Rattanawong https://orcid.org/0000-0001-9419-5854 Tanawan Riangwiwat https://orcid.org/0000-0002-8098-6257

REFERENCES

- Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.
- **2.** Rodes-Cabau J. Transcatheter aortic valve implantation: Current and future approaches. Nat Rev Cardiol. 2011;9:15-29.
- Kahn MR, Robbins MJ, Kim MC, Fuster V. Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol. 2013; 10:261-273.
- Dellegrottaglie S, Saran R, Gillespie B, et al. Prevalence and predictors of cardiovascular calcium in chronic kidney disease (from the prospective longitudinal RRI-CKD study). Am J Cardiol. 2006;98:571-576.
- Thourani VH, Keeling WB, Sarin EL, et al. Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. Ann Thorac Surg. 2011;91:1798-1806. discussion 806–807.
- 6. D'Errigo P, Moretti C, D'Ascenzo F, et al. Transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in patients with chronic kidney disease stages 3b to 5. Ann Thorac Surg. 2016;102:540-547.

- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603-605.
- 8. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137-147.
- Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2005;67:2089-2100.
- Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The valve academic research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60:1438-1454.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
- Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046-1055.
- Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of betweenstudy heterogeneity in meta-analysis: Proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37:1148-1157.
- 15. Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN aortic bioprosthesis European outcome (SOURCE) registry: The European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2011;124: 425-433.
- Makki N, Lilly SM. Advanced chronic kidney disease: Relationship to outcomes post-TAVR, a meta-analysis. Clin Cardiol. 2018;41:1091-1096.
- 17. Levi A, Codner P, Masalha A, et al. Predictors of 1-year mortality after Transcatheter aortic valve implantation in patients with and without advanced chronic kidney disease. Am J Cardiol. 2017;120: 2025-2030.
- Conrotto F, Salizzoni S, Andreis A, et al. Transcatheter aortic valve implantation in patients with advanced chronic kidney disease. Am J Cardiol. 2017;119:1438-1442.
- Hansen JW, Foy A, Yadav P, et al. Death and dialysis after transcatheter aortic valve replacement: An analysis of the STS/ACC TVT registry. JACC Cardiovasc Interv. 2017;10:2064-2075.
- 20. Allende R, Webb JG, Munoz-Garcia AJ, et al. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: Insights on clinical outcomes and prognostic markers from a large cohort of patients. Eur Heart J. 2014;35:2685-2696.
- 21. D'Ascenzo F, Moretti C, Salizzoni S, et al. 30 days and midterm outcomes of patients undergoing percutaneous replacement of aortic valve according to their renal function: A multicenter study. Int J Cardiol. 2013;167:1514-1518.
- 22. Dumonteil N, van der Boon RM, Tchetche D, et al. Impact of preoperative chronic kidney disease on short- and long-term outcomes after transcatheter aortic valve implantation: A pooled-RotterdAm-Milano-Toulouse in collaboration plus (PRAGMATIC-plus) initiative substudy. Am Heart J. 2013;165:752-760.
- Nguyen TC, Babaliaros VC, Razavi SA, et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2013;146:1399-1406. discussion 13406-13407.
- **24.** Thourani VH, Forcillo J, Beohar N, et al. Impact of preoperative chronic kidney disease in 2,531 high-risk and inoperable patients undergoing transcatheter aortic valve replacement in the PARTNER trial. Ann Thorac Surg. 2016;102:1172-1180.
- 25. Yamamoto M, Hayashida K, Mouillet G, et al. Prognostic value of chronic kidney disease after transcatheter aortic valve implantation. J Am Coll Cardiol. 2013;62:869-877.
- 26. Ferro CJ, Law JP, Doshi SN, et al. Dialysis following transcatheter aortic valve replacement: Risk factors and outcomes: An analysis from the UKTAVI (transcatheter aortic valve implantation) registry. JACC Cardiovasc Interv. 2017;10:2040-2047.
- Gupta T, Goel K, Kolte D, et al. Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:2050-2060.

- Codner P, Levi A, Gargiulo G, Praz F, Hayashida K, Watanabe Y, et al. Impact of renal dysfunction on results of transcatheter aortic valve replacement outcomes in a large multicenter cohort. Am J Cardiol. 2016;118:1888-1896.
- 29. •••
- **30.** Wessely M, Rau S, Lange P, Kehl K, Renz V, Schonermarck U, et al. Chronic kidney disease is not associated with a higher risk for mortality or acute kidney injury in transcatheter aortic valve implantation. Nephrol Dial Transplant. 2012;27:3502-3508.
- Rahman MS, Sharma R, Brecker SJD. Transcatheter aortic valve implantation in patients with pre-existing chronic kidney disease. Int J Cardiol Heart Vasc. 2015;8:9-18.
- **32.** Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014;13:823-833.
- Lau WL, Huisa BN, Fisher M. The cerebrovascular-chronic kidney disease connection: Perspectives and mechanisms. Transl Stroke Res. 2017;8:67-76.

34. Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29:29-40.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Rattanawong P, Kanitsoraphan C, Kewcharoen J, et al. Chronic kidney disease is associated with increased mortality and procedural complications in transcatheter aortic valve replacement: a systematic review and metaanalysis. *Catheter Cardiovasc Interv.* 2019;94:E116-E127. https://doi.org/10.1002/ccd.28102